Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;23(6):940-946.
doi: 10.1038/s41590-022-01212-3. Epub 2022 May 9.

Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose

Yaniv Lustig #  1   2   3 , Tal Gonen #  2   4 , Lilac Meltzer  2   4 , Mayan Gilboa  2   4 , Victoria Indenbaum  1 , Carmit Cohen  4 , Sharon Amit  5 , Hanaa Jaber  4 , Ram Doolman  6 , Keren Asraf  6 , Carmit Rubin  4 , Ronen Fluss  7 , Ella Mendelson  1   2 , Laurence Freedman  7 , Gili Regev-Yochay  8   9 , Yitshak Kreiss  2   10
Affiliations

Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose

Yaniv Lustig et al. Nat Immunol. 2022 Jun.

Abstract

As the effectiveness of a two-dose messenger RNA (mRNA) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine regimen decreases with time, a third dose has been recommended. Here, we assessed immunogenicity, vaccine effectiveness and safety of the third BNT162b2 vaccine dose in a prospective cohort study of 12,413 healthcare workers (HCWs). Anti-RBD immunoglobulin G (IgG) levels were increased 1.7-fold after a third dose compared with following the second dose. Increased avidity from 61.1% (95% confidence interval (CI), 56.1-66.7) to 96.3% (95% CI, 94.2-98.5) resulted in a 6.1-fold increase in neutralization titer. Peri-infection humoral markers of 13 third-dose Delta variant of concern (VOC) breakthrough cases were lower compared with 52 matched controls. Vaccine effectiveness of the third dose relative to two doses was 85.6% (95% CI, 79.2-90.1). No serious adverse effects were reported. These results suggest that the third dose is superior to the second dose in both quantity and quality of IgG antibodies and safely boosts protection from infection.

PubMed Disclaimer

References

    1. Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. 385, 187–189 (2021). - DOI - PubMed
    1. Bernal, J. L. et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. Preprint at medRxiv https://doi.org/10.1101/2021.03.01.21252652 (2021).
    1. Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. 385, e83 (2021). - DOI - PubMed
    1. Dagan, N. et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1970 (2021). - DOI - PubMed
    1. Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397, 1819–1829 (2021). - DOI - PubMed - PMC

Publication types

Supplementary concepts